



First name: Monireh

Last name: Mohsenzadegan

**Tel: +989124248518E-mail:
monirehmohsenzadegan@gmail.com**

Mohsenzadegan.m@iums.ac.ir

Education

2008-2014 Ph.D., Immunology, Iran University of Medical Sciences, Tehran, Iran

2006-2008 MS.c., Immunology, Tehran University of Medical Sciences, Tehran, Iran

2001-2004 B.Sc, laboratory sciences, Tehran University of Medical Sciences, Tehran, Iran

Category of Research

Tumor Immunology

Academic degree

Assistant Professor

Affiliation

Department of Medical Laboratory Science, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran

Course Teaching

Medical students of Iran university of medical sciences and AJA university of medical sciences

Teaching titles:

Vaccination
Tumor immunology
Autoimmune diseases
Tolerance
Widal test
ASO test
Wright test
ELISA
RF/CRP/beta HCG/ RPR tests

Ph.D students of Iran university of medical sciences

Teaching titles:

Immunohistochemistry
Tissue Microarray
Flow cytometry

M.Sc students of Iran university of medical sciences

Teaching titles:

Immunohistochemistry
Flow cytometry
ELISA
Tests of phagocytosis

Fellowship of laboratory sciences of Iran university of medical sciences

Teaching titles:

Immunohistochemistry and tissue microarray
Tumor markers
Diagnostic Testing and Interpretation of Tests for Autoimmunity

B.Sc students of Iran university of medical sciences

Teaching titles:

Innate immunity
B cell development
T cell development
Tolerance
Complement system
Autoimmune diseases
Tumor immunology
Widal test
ASO test
ELISA
RF/CRP/beta HCG tests
NBT test

Published articles

- 1) **Mohsenzadegan M**, Peng RW, Roudi R. Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape. *J Cell Physiol.* 2020 Jan;235(1):74-86.
- 2) Sharifi L, Nowroozi MR, Amini E, Arami MK, Ayati M, **Mohsenzadegan M***. A review on the role of M2 macrophages in bladder cancer; pathophysiology and targeting. *Int Immunopharmacol.* 2019 Sep 12;76:105880.
- 3) **Mohsenzadegan M**, Saebi F, Yazdani M, Abolhasani M, Saemi N, Jahanbani F, Farajollahi MM. Autoantibody against new gene expressed in prostate protein is traceable in prostate cancer patients. *Biomark Med.* 2018Oct;12(10):1125-1138.
- 4) Kalantari E, Abolhasani M, Roudi R, Farajollahi MM, Farhad S, Madjd Z, Askarian-Amiri S, **Mohsenzadegan M***. Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer. *Int J Exp Pathol.* 2019Apr;100(2):123-132.
- 5) **Mohsenzadegan M**, Madjd Z, Asgari M, Abolhasani M, Shekarabi M, Taeb J, Sharifabrizi A. Reduced expression of NGEF is associated with high-grade prostate cancers: a tissue microarray analysis. *Cancer Immunol Immunother.* 2013Oct;62(10):1609-18.
- 6) **Mohsenzadegan M**, Shekarabi M, Madjd Z, Asgari M, Abolhasani M, Tajik N, Farajollahi MM. Study of NGEF expression pattern in cancerous tissues provides novel insights into prognostic marker in prostate cancer. **Biomarkers in Medicine.** 2015; 9(4):391-401.
- 7) **Mohsenzadegan M***, Seif F, Farajollahi MM, Khoshmirsafa M. Anti-Oxidants as Chemopreventive Agents in Prostate Cancer: A Gap Between Preclinical and Clinical Studies. *Recent Pat Anticancer Drug Discov.* 2018;13(2):224-239.

- 8) Seif F, Sharifi L, Khoshmirsafa M, Mojibi Y, **Mohsenzadegan M***. A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer. *Curr Drug Targets*. 2019;20(7):789-798.
- 9) Roudi R., Mohammadi SR, Roudbary M, **Mohsenzadegan M***. Lung cancer and β -glucans: review of potential therapeutic applications; *Invest New Drugs* ; 2017 Aug;35(4):509-517.
- 10) **Mohsenzadegan M**, Sharifi R, Taromi N, Farajollahi MM. Evaluation of Direct Effect of Testosterone on NGEP and LMO1 Expression in LNCaP Prostate Cancer Cells; *Current Biomarkers*;2017, DOI: 10.2174/2468422807666170222091437.
- 11) **Mohsenzadegan M**, Tajik N, Madjd Z, Shekarabi M, Farajollahi MM. Study of NGEP expression in androgen sensitive prostate cancer cells; a potential target for immunotherapy. *Medical Journal of Islamic Republic of Iran*.2015;29:159.
- 12) **Mohsenzadegan M**, Mohammad Reza Fayazi, Mohsen Abdolmaleki, Masoomeh Bakhshayesh, Farhad Seif, Kazem Mousavizadeh. Direct immunomodulatory influence of IFN- β on human astrocytoma cells. *Immunopharmacol Immunotoxicol*.2015;37(2):214-9.
- 13) **Mohsenzadegan M**, Fatthahi Fa, Fattahi F, Mirshafiey A, Fazlollahi MR, Naderi F, Movahedi M, Pourpak Z. Altered Pattern of Naïve and Memory B cells and B1 Cells in Patients with Chronic Granulomatous Disease. *Iran J Allergy Asthma Immunol*. June 2014; 13(3):157-165.
- 14) **Mohsenzadegan M**, Mirshafiey A. The immunopathogenic role of reactive oxygen species in Alzheimer disease. *Iran J Allergy Asthma Immunol*. 2012 Sep;11(3):203-16.
- 15) Esfidani M, Ayatollahi Mousavi SA, Yazdanparast A, Shafiee M and **Mohsenzadegan M**. Determination of Changes in the Expression of MIR-212 and EGFR Genes in Clinical Samples from Areas Infected with *Trichophyton rubrum* Compared with Non-Infected Areas. *Jundishapur J Microbiol*. 2018; 11(11):e62885
- 16) Shahrabi Farahani M, **Mohsenzadegan M**, Taeb J, Farajollahi MM. In-vitro prostate cancer biomarker detection by directed conjugation of anti-PSCA antibody to super paramagnetic iron oxide nanoparticles. *Med J Islam Repub Iran*. 2019(12 March);33:16.

- 17) Gholipour-Kanani A, **Mohsenzadegan M**, Fayyazi M, Bahrami H, Samadikuchaksaraei A. Poly (ϵ -caprolactone)-chitosan-poly (vinyl alcohol) nanofibrous scaffolds for skin excisional and burn wounds in a canine model. *IET Nanobiotechnol.* 2018Aug;12(5):619-625.
- 18) Jamalpoor Z, Asgari A, Lashkari MH, Mirshafiey A, **Mohsenzadegan M***. Modulation of Macrophage Polarization for Bone Tissue Engineering Applications. *Iran J Allergy Asthma Immunol.* 2018Oct 7;17(5):398-408.
- 19) Sharifi L, Tavakolinia N, Kiaee F, Rezaei N, **Mohsenzadegan M**, Shariat M, Yazdani R, Mirshafiey A, Aghamohammadi A, Azizi G. A Review on Defects of Dendritic Cells in Common Variable Immunodeficiency. *Endocr Metab Immune Disord Drug Targets*; 2017;17(2):100-113.
- 20) Seif F, Khoshmirsafa M, Aazami H, **Mohsenzadegan M**, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. *Cell Commun Signal*; 2017Jun 21;15(1):23.
- 21) Sharifi L, **Mohsenzadegan M**, Aghamohammadi A, Rezaei N, Tofighi Zavareh F, Bokaie S, Moshiri M, Azizi G, Mirshafiey A, Aghazadeh Z. Immunomodulatory effect of G2013 (α -L-Guluronic acid) on the TLR2 and TLR4 in human mononuclear cells. *Curr Drug Discov Technol.* 2018;15(2):123-131.
- 22) Sharifi L, Aghamohammadi A, **Mohsenzadegan M**, Rezaei N, Towfighi Zavareh F, Moshiri M, Bokaie S, Barati A, Sayedi SJ, Azizi GH, Mirshafiey A. Immunomodulation of TLR2 and TLR4 by G2013 (α -L-Guluronic acid) in COVID Patients. *International Journal of Pediatrics* July. 2017, Page 5327-5337.
- 23) Naderi beni F, Fattahi F, Mirshafiey A, Ansari M, **Mohsenzadegan M**, Movahedi M, Pourpak Z, Moin M. Increased production of nitric oxide by neutrophils from patients with chronic granulomatous disease on interferon-gamma treatment. *Int Immunopharmacol.* 2012Apr;12(4):689-93.
- 24) Mirshafiey A, **Mohsenzadegan M**. Opioids and opioid receptor in multiple sclerosis. *The journal of Chinese clinical medicine.* March 2010; 5:3.
- 25) Mirshafiey A, **Mohsenzadegan M**. TGF- β as a promising option in the treatment of multiple sclerosis. *Neuropharmacology.* 2009 May-Jun;56(6-7):929-36.

- 26) Mirshafiey A, **Mohsenzadegan M**. Antioxidant therapy in multiple sclerosis. *Immunopharmacol Immunotoxicol*.2009;31(1):13-29.
- 27) Mirshafiey A ,**Mohsenzadegan M**. Immunotoxicological effects of reactive oxygen species in multiple sclerosis. *J of Chinese clinical medicine*. July2008; 3:7.
- 28) Mirshafiey A, **Mohsenzadegan M**. The role of reactive oxygen species in immunopathogenesis of rheumatoid arthritis. *Iran J Allergy Asthma Immunol*. 2008Dec;7(4):195-202.
- 29) Namaki S, **Mohsenzadegan M**, Mirshafiey A. Superoxide dismutase: A light horizon in treatment of multiple sclerosis. *Journal of Chinese Clinical Medicine*;2009, Vol. 4 Issue 10, p585.
- 30) Khoshmirsafa M, Seif F, **Mohsenzadegan M**, Najafi M, Mokhtarian K, Shekarabi M. Circulating microRNAs, valuable biomarkers in biological fluids. *RJMS* 2017, 24(160): 22-36.
- 31) Gholipour-Kanania A, Samadikuchaksaraei A, **Mohsenzadegan M**, Fayyazi MR. Nanofibrous scaffolds from chitosan and poly(caprolactone) for excision wound healing application in canine model. *Material today: proceeding*. Volume 5, Issue 7, Part 3, 2018, Pages 15629-15634.
- 32) Khalvandi A, Abolhasani M, Madjd Z, Sharifi L, Bakhshi P, **Mohsenzadegan M***. Reduced cytoplasmic expression of MAGE-A2 predicts tumor aggressiveness and survival: an immunohistochemical analysis. *World J Urol*. 2021 Jun;39(6):1831-1843.
- 33) Samaee H, **Mohsenzadegan M**, Ala S, Maroufi SS, Moradimajd P. Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease. *Int Immunopharmacol*. 2020 Dec;89(Pt A):107018.
- 34) Chizari M, Fani-Kheshti S, Taeb J, Farajollahi MM, **Mohsenzadegan M***. The Anti-Proliferative Effect of a Newly-Produced Anti-PSCA-Peptide Antibody by Multiple Bioinformatics Tools, on Prostate Cancer Cells. *Recent Pat Anticancer Drug Discov*. 2021;16(1):73-83.
- 35) Aghamajidi A, Raoufi E, Parsamanesh G, Jalili A, Salehi-Shadkami M, Mehrali M, **Mohsenzadegan M***. The attentive focus on T cell-mediated autoimmune pathogenesis of psoriasis, lichen planus and vitiligo. *Scand J Immunol*. 2021 Apr;93(4):e13000.
- 36) Latifi A, Ghanizadeh-Vesali S, Hosseini S, **Mohsenzadegan M***. Clinical significance of peripheral blood CD11b+/CD33+/HLA-DR- myeloid cells in infants and children with infectious diseases and increased CRP. *Med J Islam Repub Iran*. 2020 Aug 5;34:92.
- 37) Khalvandi A, Abolhasani M, Madjd Z, Shekarabi M, Kourosch-Arami M, **Mohsenzadegan M***. Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer. *APMIS*. 2021 Jun;129(6):291-303.

- 38) **Mohsenzadegan M**, Bavandpour P, Nowroozi MR, Amini E, Kourosh-Arami M, Momeni SA, Bokaie S, Sharifi L. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer. *Endocr Metab Immune Disord Drug Targets*. 2021;21(12):2131-2146.
- 39) **Mohsenzadegan M***, Moghbeli F, Mirshafiey A, Farajollahi MM. Anti-tumor effect of M2000 (β -d-mannuronic acid) on the expression of inflammatory molecules in the prostate cancer cell. *Immunopharmacol Immunotoxicol*. 2021 Aug;43(4):419-430.
- 40) Bagherian Z, Mirshafiey A, **Mohsenzadegan M***, Farajollahi MM. Evaluation of G2013 (α -L-guluronic acid) efficacy on PC-3 cells through inhibiting the expression of inflammatory factors. *Clin Exp Pharmacol Physiol*. 2022 Feb;49(2):254-263.
- 41) Saeednejad Zanjani L, Razmi M, Fattahi F, Kalantari E, Abolhasani M, Saki S, Madjd Z, **Mohsenzadegan M***. Overexpression of melanoma-associated antigen A2 has a clinical significance in embryonal carcinoma and is associated with tumor progression. *J Cancer Res Clin Oncol*. 2022 Mar;148(3):609-631.
- 42) **Mohsenzadegan M***, Razmi M, Vafaei S, Abolhasani M, Madjd Z, Saeednejad Zanjani L, Sharifi L. Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer. *Sci Rep*. 2022 Jan 12;12(1):599.
- 43) Abedini F, Mohammadi SR, Dahmardehei M, Ajami M, Salimi M, Khalandi H, **Mohsenzadegan M**, Seif F, Shirvan BN, Yaalimadad S, Roudbary M, Rodrigues CF. Enhancing of Wound Healing in Burn Patients through *Candida albicans* β -Glucan. *J Fungi (Basel)*. 2022 Mar 4;8(3):263.
- 44) Mojibi Y, Seif F, Mojibi N, Aghamajidi A, **Mohsenzadegan M***, Torang HA. Efficacy of immunotherapy in obese patients with cancer. *Immunopharmacol Immunotoxicol*. 2022 Aug;44(4):471-483.
- 45) **Mohsenzadegan M**, Nowroozi MR, Fotovvat A, Bavandpour Baghshahi P, Bokaie S, Inanloo SH, Sharifi L. The prospect of targeting T cell immunoglobulin and mucin-domain containing-3 in renal cell carcinoma immunotherapy. *Scand J Immunol*. 2022 Sep;96(3):e13197.
- 46) Aghamajidi A, Ousati Ashtiani Z, **Mohsenzadegan M***, Tajik N, Ghafoori Yazdi M, Sharifi L, Nowroozi MR. Molecular Characteristics of Bladder Tumor: Increased Gene Expression of MAGE-A6 and MAGE-A11 with Decreased MicroRNA-34a and MicroRNA-125b. *Iran J Allergy Asthma Immunol*. 2022 Oct 26;21(5):561-573.
- 47) Raoufi E, Hosseini F, Onagh B, Salehi-Shadkami M, Mehrali M, **Mohsenzadegan M**, Ho JQ, Bigdelou B, Sepand MR, Webster TJ, Zanganeh S, Farajollahi MM. Designing and developing a sensitive and specific SARS-CoV-2 RBD IgG detection kit for identifying positive human samples. *Clin Chim Acta*. 2023 Mar 1;542:117279.

48) Nayerpour Dizaj T, Jafari-Gharabaghloou D, Farhoudi Sefidan Jadid M, Jahanban R, Rahimi M, Farajollahi MM, **Mohsenzadegan M***, Zarghami N. Fabrication of Antibody Conjugated Super Magnetic Oxide Nanoparticles for Early Detection of Prostate Cancer. *Asian Pac J Cancer Prev.* 2023 Jun 1;24(6):2089-2097.

49) Bakhshi P, Nourizadeh M, Sharifi L, Farajollahi MM, **Mohsenzadegan M***. Development of dendritic cell loaded MAGE-A2 long peptide; a potential target for tumor-specific T cell-mediated prostate cancer immunotherapy. *Cancer Cell Int.* 2023 Nov 11;23(1):270.

50) Kourosh-Arami M, Hosseini N, **Mohsenzadegan M**, Komaki A, Joghataei MT. Neurophysiologic implications of neuronal nitric oxide synthase. *Rev Neurosci.* 2020 Aug 27;31(6):617-636.

پایان نامه ها

- ۱- تولید ایمونوتوکسین با استفاده از آنتی بادی علیه PSCA و توکسین نوترکیب تولید شده در آزمایشگاه بیوتکنولوژی: هدف قرار دادن سلولهای سرطان پروستات (PC3) در شرایط *In vitro*
- ۲- تخلیص آنتی بادی سلول بنیادی پروستات PSCA و تصویربرداری به وسیله کنژوگاسیون آن با ذرات نانو مغناطیسی آهن
- ۳- سنجش بیان پروتئین PSCA پروستاتی در رده سلولی موشی T14 ترانسفکت شده با ژن PSCA
- ۴- کلون، بیان و تخلیص نواحی دارای بالاترین خاصیت آنتی ژنیک پروتئین Spike و ویروس کرونا در مخمر پیکیا پاستوریس و بررسی آنتی ژنیسیته آن در نمونه های سرمی بیماران مبتلا به ویروس کرونا
- ۵- ارزیابی میزان بیان پروتئین های MAGEA2 و MAGEA3 بر روی انواع تومورهای سرطان بیضه و ارتباط میزان بیان این مارکرها با پروگنوز و خصوصیات بالینی و پاتولوژیکی بیماران
- ۶- فعالسازی سلول های دندریتیک لود شده با آنتی ژن های نوترکیب MAGE-A2 و PSCA جهت بررسی پاسخ های ایمنی در شرایط *invitro* در بیماران مبتلا به سرطان پروستات
- ۷- ارزیابی اثر ضدالتهابی لاکتوباسیلوس سالیواریوس بر بیان ژنهای IL-10, IL-8, MyD-88, NF-Kb و تولید سیتوکین های IL-8 و IL-10 در رده سلولی سرطان معده
- ۸- ارزیابی نقش سوپرناتانت لاکتوباسیلوس بولگاریکوس برعلیه عفونت هلیکوباکتر پیلوری از طریق تعدیل پاسخ های ایمنی در PBMC
- ۹- سنجش بیان پروتئین TPTE در نمونه های بافتی بیماران مبتلا به سرطان پروستات در مقایسه با افراد مبتلا به هایپرپلازی خوش خیم پروستات و هدف قرار دادن رده های سلولی بیان کننده TPTE با استفاده از آنتی بادی-های تولید شده
- ۱۰- بررسی اثر هدفمند ایمونولیپوزوم دوکسوروبیسین روی رسپتور TPTE در رده سلولهای سرطانی پروستات و سینه
- ۱۱- ارزیابی پاسخهای ایمنی سلولی از طریق سلولهای دندریتیک در معرض قرار گرفته با ساختارهای پپتید اپی توپی حامل نواحی ایمنودامیننت گلیکوپروتئین ۹۶ و کالرتیکولین متصل به اپی توپهای ایمنوژنیک E7 ویروس پاپیلوما انسانی نوع ۱۶

اختراع

عنوان: آنتی بادی ضد پپتید PSCA محل ثبت: سازمان ثبت اسناد و املاک کشور

عنوان : آنتی بادی ضد پپتید NGEP محل ثبت: سازمان ثبت اسناد و املاک کشور